Absolute Bioavailability of Bosutinib in Healthy Subjects From an Open-Label, Randomized, 2-Period Crossover Study.
Hsyu, Poe-Hirr; Pignataro, Daniela Soriano; Matschke, Kyle.
Clin Pharmacol Drug Dev
; 7(4): 373-381, 2018 05.
Artigo em Inglês | MEDLINE | ID: mdl-29058816
A randomized, crossover, placebo- and moxifloxacin-controlled study to evaluate the effects of bosutinib (SKI-606), a dual Src/Abl tyrosine kinase inhibitor, on cardiac repolarization in healthy adult subjects.
Safety and efficacy of bosutinib in fourth-line therapy of chronic myeloid leukemia patients.
A clinical study to examine the potential effect of lansoprazole on the pharmacokinetics of bosutinib when administered concomitantly to healthy subjects.
Effect of rifampin on the pharmacokinetics of bosutinib, a dual Src/Abl tyrosine kinase inhibitor, when administered concomitantly to healthy subjects.
Ascending single-dose study of the safety profile, tolerability, and pharmacokinetics of bosutinib coadministered with ketoconazole to healthy adult subjects.
Bosutinib versus Placebo for Autosomal Dominant Polycystic Kidney Disease.
Effect of multiple-dose osimertinib on the pharmacokinetics of simvastatin and rosuvastatin.
A phase I ascending single-dose study of the safety, tolerability, and pharmacokinetics of bosutinib (SKI-606) in healthy adult subjects.
Effect of ketoconazole on the pharmacokinetics of oral bosutinib in healthy subjects.
Application of Physiologically Based Pharmacokinetic Modeling to the Understanding of Bosutinib Pharmacokinetics: Prediction of Drug-Drug and Drug-Disease Interactions.